Tim Shannon, M.D.

For more than 25 years, Dr. Shannon has been an entrepreneur, executive, researcher, professor, and practicing physician in pulmonary and critical care medicine. An investor with Canaan Partners since 2009, Dr. Shannon helps companies grow from their earliest stages to funded companies, creating value through partnerships, M&A and IPOs. He was among the earliest institutional investors and remains on the board of CytomX Therapeutics, which completed a $92 million IPO in October 2015, and acted as co-lead Series A investor in Civitas Therapeutics, acquired by Acorda Therapeutics in October 2014 for $525 million. He also was a Series A investor in Novira Therapeutics, acquired by Johnson & Johnson in December 2015, and he serves on the boards of IDEAYA Biosciences, NextCure, Spyryx Biosciences and VaxInnate Corporation. Prior to Canaan, Dr. Shannon was president and CEO of CuraGen and senior vice president and head of global clinical development for Bayer’s Pharmaceutical Business Group. He began his career as assistant professor of the pulmonary and critical care division at Yale University School of Medicine. Dr. Shannon received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut. He also holds a B.A. in chemistry from Amherst College.

© Copyright 2024 - Vivace Therapeutics, Inc.